Esperion Therapeutics (ESPR) Releases Quarterly Earnings, Hits Estimates
Esperion Therapeutics (NASDAQ:ESPR) posted its quarterly earnings results on Tuesday. The company reported $0.60 earnings per share for the quarter, meeting the analysts’ consensus estimate of $0.60, AR Network reports.
Esperion Therapeutics (NASDAQ:ESPR) opened at 16.00 on Tuesday. Esperion Therapeutics has a one year low of $10.90 and a one year high of $20.10. The stock has a 50-day moving average of $15.0 and a 200-day moving average of $14.94. The company’s market cap is $245.8 million.
Esperion Therapeutics Inc is a United States-based biopharmaceutical company focused on the research, development and commercialization of therapies for the treatment of patients with elevated levels of low-density lipoprotein cholesterol (NASDAQ:ESPR) and other cardiometabolic risk factors.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.